Abstract: Objective To study the efficacy and economic benefit of extended-infusion of biapenem in treatment of severe pneumonia. Methods 58 patients were divided into 3 h extended-infusion group (EI) and 0.5 h intermit-infusion group (TI), given biapenem 0.3 g, q12 h~q6 h, respectively.The clinical effect was compared, and the pharmacoeconomics was analyzed by the least cost analysis. Results The effective rate of EI group was 63.33%, and the average cost was ( 4 057±296) yuan. The effective rate of TI group was 60.71%, the average cost was (5 624±308 ) yuan. The cost of EI group was significantly lower than that of the TI group (P <0.05). Conclusion It has prominent superiority for extended-infusion of biapenem to treat severe pneumonia, deserving of popularization and application.

Key words: biapenem, extended-infusion, pharmacoeconomics